ZA200307007B - Benzimidazoles that are useful in treating sexual dysfunction. - Google Patents
Benzimidazoles that are useful in treating sexual dysfunction. Download PDFInfo
- Publication number
- ZA200307007B ZA200307007B ZA200307007A ZA200307007A ZA200307007B ZA 200307007 B ZA200307007 B ZA 200307007B ZA 200307007 A ZA200307007 A ZA 200307007A ZA 200307007 A ZA200307007 A ZA 200307007A ZA 200307007 B ZA200307007 B ZA 200307007B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzimidazole
- methyl
- hydrogen
- compound
- piperazin
- Prior art date
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title claims description 79
- 231100000872 sexual dysfunction Toxicity 0.000 title claims description 79
- 150000001556 benzimidazoles Chemical class 0.000 title description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 249
- 239000001257 hydrogen Substances 0.000 claims description 249
- 150000001875 compounds Chemical class 0.000 claims description 228
- 238000000034 method Methods 0.000 claims description 187
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 181
- 239000000203 mixture Substances 0.000 claims description 130
- 241000124008 Mammalia Species 0.000 claims description 96
- 229940002612 prodrug Drugs 0.000 claims description 89
- 239000000651 prodrug Substances 0.000 claims description 89
- 150000003839 salts Chemical class 0.000 claims description 89
- 229910052736 halogen Inorganic materials 0.000 claims description 85
- 150000002367 halogens Chemical class 0.000 claims description 85
- 150000001408 amides Chemical class 0.000 claims description 78
- 150000002148 esters Chemical class 0.000 claims description 78
- -1 cyano, formyl Chemical group 0.000 claims description 57
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 30
- FRPJGTNLZNXQEX-UHFFFAOYSA-N 2-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-1H-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 FRPJGTNLZNXQEX-UHFFFAOYSA-N 0.000 claims description 25
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 25
- XJHRQPODSUYKOJ-UHFFFAOYSA-N 2-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=NC=CC=N1 XJHRQPODSUYKOJ-UHFFFAOYSA-N 0.000 claims description 24
- CBDXXUZXRDBOGH-UHFFFAOYSA-N 6-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-ol Chemical compound N1=CC(O)=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 CBDXXUZXRDBOGH-UHFFFAOYSA-N 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 20
- KMKXKQTUXKYJDN-WBPXWQEISA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 KMKXKQTUXKYJDN-WBPXWQEISA-N 0.000 claims description 19
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 18
- DFYAIIXQJKVNLK-UHFFFAOYSA-N 2-[(4-pyridin-2-ylpiperidin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCC1C1=CC=CC=N1 DFYAIIXQJKVNLK-UHFFFAOYSA-N 0.000 claims description 17
- VZEBBCOAASDUOG-UHFFFAOYSA-N 2-methylpropyl 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole-1-carboxylate Chemical compound N=1C2=CC=CC=C2N(C(=O)OCC(C)C)C=1CN(CC1)CCN1C1=CC=CC=N1 VZEBBCOAASDUOG-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 16
- NFCYVMDRDOBUCA-UHFFFAOYSA-N 2-[(2-methyl-4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound C1CN(CC=2NC3=CC=CC=C3N=2)C(C)CN1C1=CC=CC=N1 NFCYVMDRDOBUCA-UHFFFAOYSA-N 0.000 claims description 15
- 239000000674 adrenergic antagonist Substances 0.000 claims description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 14
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 14
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 14
- DZNZGCABZHIRPU-UHFFFAOYSA-N 2-[(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC=1)CCC=1C1=CC=CC=C1 DZNZGCABZHIRPU-UHFFFAOYSA-N 0.000 claims description 13
- QXIHXJBCHQNHHK-UHFFFAOYSA-N 4,6-dibromo-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC(Br)=CC(Br)=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 QXIHXJBCHQNHHK-UHFFFAOYSA-N 0.000 claims description 13
- IRHVKGPETODEAT-UHFFFAOYSA-N 2-[(4-phenylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=C1 IRHVKGPETODEAT-UHFFFAOYSA-N 0.000 claims description 11
- FXHHMDYNRLYBIP-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]benzonitrile Chemical compound N#CC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 FXHHMDYNRLYBIP-UHFFFAOYSA-N 0.000 claims description 10
- ZSKFERSPBICNGI-UHFFFAOYSA-N 6-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 ZSKFERSPBICNGI-UHFFFAOYSA-N 0.000 claims description 10
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 10
- AREKWDVNONIIPS-UHFFFAOYSA-N [2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazol-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C1CN(C=2N=CC=CC=2)CCN1CC1=NC2=CC=CC=C2N1C(=O)N1CCCC1 AREKWDVNONIIPS-UHFFFAOYSA-N 0.000 claims description 10
- 201000001881 impotence Diseases 0.000 claims description 10
- UZJFFJHTJQGBFA-UHFFFAOYSA-N n-[2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 UZJFFJHTJQGBFA-UHFFFAOYSA-N 0.000 claims description 10
- GVEYDRPQIGZJMX-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]phenol Chemical compound OC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 GVEYDRPQIGZJMX-UHFFFAOYSA-N 0.000 claims description 9
- BZIHDTKDCIILSI-UHFFFAOYSA-N 2-[[4-(2-methylsulfanylphenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CSC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 BZIHDTKDCIILSI-UHFFFAOYSA-N 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- JJQKBCIECKEMBR-UHFFFAOYSA-N 4-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]phenol Chemical compound C1=CC(O)=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 JJQKBCIECKEMBR-UHFFFAOYSA-N 0.000 claims description 8
- 206010013654 Drug abuse Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- JBDSKBUSDDHPEB-UHFFFAOYSA-N n,n-dimethyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole-1-carboxamide Chemical compound N=1C2=CC=CC=C2N(C(=O)N(C)C)C=1CN(CC1)CCN1C1=CC=CC=N1 JBDSKBUSDDHPEB-UHFFFAOYSA-N 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- 206010012374 Depressed mood Diseases 0.000 claims description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 7
- 208000019022 Mood disease Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 7
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 7
- 229940095064 tartrate Drugs 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- FLKJVYVXYMFZRE-UHFFFAOYSA-N 2-[[4-(6-methylpyridin-2-yl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CC1=CC=CC(N2CCN(CC=3NC4=CC=CC=C4N=3)CC2)=N1 FLKJVYVXYMFZRE-UHFFFAOYSA-N 0.000 claims description 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
- HSEIIOCMMFLOGG-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridine-3-carbonitrile Chemical compound N#CC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 HSEIIOCMMFLOGG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- APKCWCBYTWWSHR-UHFFFAOYSA-N 2-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound FC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 APKCWCBYTWWSHR-UHFFFAOYSA-N 0.000 claims description 3
- DIIMPNOBUZSQDU-UHFFFAOYSA-N 2-[[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound FC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 DIIMPNOBUZSQDU-UHFFFAOYSA-N 0.000 claims description 3
- WINMXTNEPXMBLG-UHFFFAOYSA-N 2-[[4-(3-methylpyridin-2-yl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 WINMXTNEPXMBLG-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- OTCBEARWFWNLRF-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]-1,3-thiazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=NC=CS1 OTCBEARWFWNLRF-UHFFFAOYSA-N 0.000 claims description 2
- STLDHJMNWBEBGX-UHFFFAOYSA-N 2-[[4-(2-ethoxyphenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CCOC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 STLDHJMNWBEBGX-UHFFFAOYSA-N 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 129
- 238000004519 manufacturing process Methods 0.000 claims 15
- NFCYVMDRDOBUCA-CQSZACIVSA-N 2-[[(2r)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]methyl]-1h-benzimidazole Chemical compound C([C@H](N(CC1)CC=2NC3=CC=CC=C3N=2)C)N1C1=CC=CC=N1 NFCYVMDRDOBUCA-CQSZACIVSA-N 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- KEGYYRUXGXROQP-UHFFFAOYSA-N 2-[[4-(2-nitrophenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 KEGYYRUXGXROQP-UHFFFAOYSA-N 0.000 claims 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- QKKFQHBDHBMWGM-UHFFFAOYSA-N 2-[[4-(2-methoxyphenyl)piperidin-1-yl]methyl]-1h-benzimidazole Chemical compound COC1=CC=CC=C1C1CCN(CC=2NC3=CC=CC=C3N=2)CC1 QKKFQHBDHBMWGM-UHFFFAOYSA-N 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 29
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 14
- 229960003638 dopamine Drugs 0.000 description 13
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 12
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 9
- 229960004046 apomorphine Drugs 0.000 description 8
- 208000004483 Dyspareunia Diseases 0.000 description 6
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 6
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 210000003016 hypothalamus Anatomy 0.000 description 6
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 6
- 229960001289 prazosin Drugs 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 229960003310 sildenafil Drugs 0.000 description 6
- 229960002613 tamsulosin Drugs 0.000 description 6
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 6
- 229960001693 terazosin Drugs 0.000 description 6
- 206010046947 vaginismus Diseases 0.000 description 6
- 229960002381 vardenafil Drugs 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000001856 erectile effect Effects 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 208000037869 female anorgasmia Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 4
- 230000018052 penile erection Effects 0.000 description 4
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000436 pro-erectile effect Effects 0.000 description 3
- 230000009329 sexual behaviour Effects 0.000 description 3
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 210000001010 olfactory tubercle Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002509 periaqueductal gray Anatomy 0.000 description 2
- 210000003814 preoptic area Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KHZNAPHBEHUIQZ-UHFFFAOYSA-N 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole-1-carboxylic acid Chemical compound N=1C2=CC=CC=C2N(C(=O)O)C=1CN(CC1)CCN1C1=CC=CC=N1 KHZNAPHBEHUIQZ-UHFFFAOYSA-N 0.000 description 1
- ATPCXZFSRSVMMW-UHFFFAOYSA-N 2-[[4-(2-chlorophenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound ClC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 ATPCXZFSRSVMMW-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229910019567 Re Re Inorganic materials 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000001257 erectogenic effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001748 islands of calleja Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
- 229950001037 quinpirole Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002813 septal nuclei Anatomy 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001030 ventral striatum Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80353701A | 2001-03-09 | 2001-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307007B true ZA200307007B (en) | 2004-12-08 |
Family
ID=25186778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307007A ZA200307007B (en) | 2001-03-09 | 2003-09-08 | Benzimidazoles that are useful in treating sexual dysfunction. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20030008878A1 (pt) |
| AR (1) | AR035768A1 (pt) |
| EC (1) | ECSP034752A (pt) |
| MY (1) | MY139385A (pt) |
| PE (1) | PE20030045A1 (pt) |
| PT (1) | PT1373220E (pt) |
| ZA (1) | ZA200307007B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022728B2 (en) * | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
| CA2251255A1 (en) * | 1998-10-20 | 2000-04-20 | Mcgill University | The use of dopaminergic agents in the management of sexual dysfunction |
-
2001
- 2001-06-05 US US09/874,484 patent/US20030008878A1/en not_active Abandoned
-
2002
- 2002-03-06 PT PT02731130T patent/PT1373220E/pt unknown
- 2002-03-08 MY MYPI20020834A patent/MY139385A/en unknown
- 2002-03-11 PE PE2002000188A patent/PE20030045A1/es not_active Application Discontinuation
- 2002-03-11 AR ARP020100870A patent/AR035768A1/es unknown
-
2003
- 2003-08-27 EC EC2003004752A patent/ECSP034752A/es unknown
- 2003-09-08 ZA ZA200307007A patent/ZA200307007B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030008878A1 (en) | 2003-01-09 |
| MY139385A (en) | 2009-09-30 |
| AR035768A1 (es) | 2004-07-07 |
| PT1373220E (pt) | 2007-08-09 |
| ECSP034752A (es) | 2004-04-28 |
| PE20030045A1 (es) | 2003-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1763523B1 (en) | Quinazolinedione derivatives as parp inhibitors | |
| JP6867295B2 (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ | |
| CN1237177A (zh) | 稠合的二环嘧啶衍生物 | |
| CN114949228A (zh) | 抗癌组合疗法 | |
| JP2018505880A (ja) | がんの治療のための化合物 | |
| EP2968316A1 (en) | Novel compounds and compositions for inhibition of fasn | |
| MXPA04006882A (es) | Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina. | |
| CN104854101A (zh) | Alk激酶抑制剂 | |
| ZA200601025B (en) | Quinazoline derivatives as angiogenesis inhibitors | |
| OA12097A (en) | 2,4-Diaminopyrimidine compounds useful as immunosuppressants. | |
| TW200831490A (en) | A method for pain treatment | |
| WO2017157792A1 (en) | Combinations of copanlisib | |
| EP1373220B1 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
| US6960589B2 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
| AU2002303128A1 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
| US20040127504A1 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
| ZA200307007B (en) | Benzimidazoles that are useful in treating sexual dysfunction. | |
| US7022728B2 (en) | Benzimidazoles that are useful in treating male sexual dysfunction | |
| MX2010012804A (es) | Derivados de dihidropirazol como moduladores de tirosina cinasa para el tratamiento de tumores. | |
| KR100863147B1 (ko) | 벤즈이미다졸 및 이를 포함하는 성 기능장애 치료용 약제학적 조성물 | |
| TW200401775A (en) | Benzimidazoles that are useful in treating sexual dysfunction |